Daratumumab, an anti‐CD38 monoclonal antibody, since its incorporation into the treatment paradigm for newly diagnosed multiple myeloma has enhanced overall survival (OS) and progression‐free survival (PFS) in both transplant eligible and ineligible patients [3, 4, 5]. Here, CD38 is linked to plasma cell myeloma.